Vertex announces new portfolio reimbursement agreement in italy including kaftrio®, symkevi® and additional indications of orkambi® and kalydeco® for eligible patients with cystic fibrosis

London--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced it has reached a new portfolio agreement with the italian medicines agency, aifa, for the reimbursement of all of vertex's approved medicines for the treatment of cystic fibrosis (cf), including kaftrio® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor. italian patients ages 12 years and older with one f508del mutation and one minimal function mutation (f/mf) or two f508del muta
VRTX Ratings Summary
VRTX Quant Ranking